The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
 
Sylvia Mina Lee
No Relationships to Disclose
 
Missak Haigentz
Stock and Other Ownership Interests - Roche
Consulting or Advisory Role - AstraZeneca
 
Liza Cosca Villaruz
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Lilly; Merck; Millennium
 
Igor Gorbatchevsky
Employment - Bayer; Iovance Biotherapeutics
 
Sam Suzuki
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie; Auxilium; GTx; Omeros; Synergy Pharmateuticals
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Susie Tanamly
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Acerta Pharma; Pharmacyclics
 
Nancy Louise Samberg
Employment - Iovance Biotherapeutics
 
Maria Fardis
Employment - Acerta Pharma; Iovance Biotherapeutics
Leadership - Acerta Pharma; Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie; Acerta Pharma; Gilead Sciences; Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - Acerta Pharma (Inst); Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; Iovance Biotherapeutics